[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524830":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":29,"locations":38,"responsibleParty":61,"collaborators":10,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":10,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":10,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":85,"whyStopped":10,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"successful group",null,"CTO PCI Technical success ,deployment of a balloon or stent with final antegrade TIMI flow grade 2 or 3, residual stenosis \\\u003C30% , and no significant side branch occlusion.",[13],"Procedure: CTO PCI",{"label":15,"type":10,"description":16,"interventionNames":17},"unsuccessful group","CTO PCI Technical unsuccess",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"PROCEDURE","CTO PCI","percutaneous coronary intervention",[9,15],[25],{"name":26,"affiliation":27,"role":28},"Chunjian Li, Dr,PhD","Study Principal Investigator","PRINCIPAL_INVESTIGATOR",[30,34],{"name":26,"role":31,"phone":32,"phoneExt":10,"email":33},"CONTACT","+86-13701465229","drcjli@hotmail.com",{"name":35,"role":31,"phone":36,"phoneExt":10,"email":37},"Kun Liu, MD","+86-18961322023","liukun2023@sina.com",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"First Affiliated Hospital of Nanjing Medical University","RECRUITING","Nanjing","Jiangsu","210029","China","CN",{"type":48,"coordinates":49},"Point",[50,51],118.77778,32.06167,{"lat":51,"lon":50},[54,59],{"name":55,"role":31,"phone":56,"phoneExt":57,"email":58},"Fuming Zhang, M.D.","+86-25-83718836","6360","jsphkj@163.com",{"name":60,"role":31,"phone":56,"phoneExt":57,"email":58},"Chai, M.D.",{"type":28,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Chunjian Li","Director of Cardiology","100524830","viable-myocardium-detected-by-hybrid-petmr-and-spect-for-the-prediction-of-the-efficacy-of-pci-in-patients-with-cto-100524830",false,"NCT06113835","Viable Myocardium Detected by Hybrid PET\u002FMR and SPECT for the Prediction of the Efficacy of PCI in Patients With CTO.","Viable Myocardium Detected by the Combination of Hybrid PET\u002FMR and SPECT Imaging for the Prediction of the Efficacy of PCI in Patients With Chronic Total Occlusion.","Inclusion Criteria:\n\n1. Age ≧ 18 years, \\\u003C 75 years;\n2. complete occlusion of the coronary artery, confirmed by coronary angiography with TIMI flow grade 0, and occlusion for ≥3 months;\n3. presence of angina or angina-equivalent symptoms ; undergo coronary intervention;\n\nExclusion Criteria:\n\n1. life expectancy \\\u003C 1 year due to non-cardiac disease;\n2. contraindications to SPECT\u002FPET\u002FMRI: pregnancy, contrast allergy, claustrophobia, history of pacemaker and ICD implantation, other ferromagnetic materials in the body;\n3. acute coronary syndrome within the last 3 months;\n4. severe valvular heart disease;\n5. haemodynamic instability;\n6. hepatic or renal insufficiency, with alanine aminotransferase (ALT) \\> 3 times the upper limit of normal or glomerular filtration rate ≤ 30 mL\u002Fmin;\n7. two or more CTO lesions;\n8. previous myocardial infarction.\n9. Others who, in the opinion o f the investigator, should not be enrolled;","ALL","18 Years","75 Years",{"count":75,"type":76},80,"ESTIMATED","OBSERVATIONAL","CTO intervention is controversial, and viable myocardium is critical to the improvement of cardiac function and prognosis of patients. However, it remains uncertain whether viable myocardium detected by Hybrid PET\u002FMR and SPECT Imaging improves the PCI efficacy in Patients With CTO.\n\nIn this investigator-initiated, prospective, single-center, observational trial, patients meeting the inclusion\u002Fexclusion criteria would be assigned to the successful group or the unsuccessful group based on the success of PCI, both undergoing pre-operative and 6-month follow-up Hybrid PET\u002FMR and SPECT imaging. The improvement of left ventricular (LV) recovery after 6 months will be observed.",[80],"Chronic Total Occlusion of Coronary Artery",[80,82,83,84],"viable myocardium","Hybrid PET\u002FMR and SPECT Imaging","Percutaneous coronary intervention","UNKNOWN","2023-10-30",{"date":88,"type":89},"2023-11-02","ACTUAL",{"date":91,"type":89},"2023-02-22",{"date":93,"type":76},"2025-03-30",{"name":5,"class":6},1]